{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:58:23Z","timestamp":1793271503293,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.rdc.2025.07.001","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T12:51:35Z","timestamp":1756731095000},"page":"e1-e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S","title":["Obesity and Comorbidity Management in Psoriatic Arthritis"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-4328","authenticated-orcid":false,"given":"Ajesh B.","family":"Maharaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-2976","authenticated-orcid":false,"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rdc.2025.07.001_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"21","key":"10.1016\/j.rdc.2025.07.001_bib2","first-page":"2095","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.001_bib3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.rdc.2025.07.001_bib4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fmed.2018.00062","article-title":"Comorbidities in spondyloarthritis","volume":"5","author":"Molto","year":"2018","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.001_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40744-020-00202-x","article-title":"The impact of comorbidity on patient-reported outcomes in psoriatic arthritis: a systematic literature review","volume":"7","author":"Canete","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"10258","key":"10.1016\/j.rdc.2025.07.001_bib6","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2025.07.001_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155217","article-title":"A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on","volume":"133","author":"Boutari","year":"2022","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.001_bib8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and psoriatic arthritis: a narrative review","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.001_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.001_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/acr.25230","article-title":"Comorbidities in early psoriatic arthritis: data from the metabolic disturbances in psoriatic arthritis cohort study","volume":"76","author":"Ishchenko","year":"2024","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.001_bib11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.22185","article-title":"Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis","volume":"66","author":"Labitigan","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2025.07.001_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/annrheumdis-2023-eular.3678","article-title":"OP0064 obesity in psoriatic arthritis is increasingly affecting men and appears less dependent of socioeconomic status than in the general population","volume":"82","author":"Stirnimann","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.001_bib13","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1016\/S2665-9913(23)00264-3","article-title":"Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis","volume":"5","author":"Eder","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.001_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.001_bib15","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/rheumatology\/keab622","article-title":"Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study","volume":"61","author":"Ogdie","year":"2022","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.001_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3899\/jrheum.210006","article-title":"Risk factors for diagnosis of psoriatic arthritis, psoriasis, rheumatoid arthritis, and ankylosing spondylitis: a set of parallel case-control studies","volume":"49","author":"Meer","year":"2022","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.001_bib17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/kes242","article-title":"Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management","volume":"52","author":"Russolillo","year":"2013","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.001_bib18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3899\/jrheum.160532","article-title":"The association between obesity and clinical features of psoriatic arthritis: a case-control study","volume":"44","author":"Eder","year":"2017","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.001_bib19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archdermatol.2010.141","article-title":"Obesity in early adulthood as a risk factor for psoriatic arthritis","volume":"146","author":"Soltani-Arabshahi","year":"2010","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.001_bib20","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2025.07.001_bib21","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3899\/jrheum.190219","article-title":"Measuring outcomes in psoriatic arthritis: comparing routine assessment of patient index data and psoriatic arthritis impact of disease","volume":"47","author":"Walsh","year":"2020","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.001_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13075-023-03248-8","article-title":"Patients with obesity have more inflamed joints and higher CRP levels during the disease course in ACPA-positive RA but not in ACPA-negative RA","volume":"26","author":"Hollander","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.001_bib23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/ijd.16933","article-title":"Obesity is associated with higher nail psoriasis disease activity and prevalence in patients with psoriatic arthritis","volume":"63","author":"Galarza-Delgado","year":"2024","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.001_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003157","article-title":"Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study","volume":"9","author":"Leung","year":"2023","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.001_bib25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","article-title":"Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis","volume":"74","author":"Eder","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.001_bib26","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","article-title":"The influence of obesity on response to tumour necrosis factor-\u03b1 inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries","volume":"55","author":"H\u00f8jgaard","year":"2016","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.001_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jbspin.2018.03.007","article-title":"Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis","volume":"86","author":"Shan","year":"2019","journal-title":"Jt Bone Spine"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.001_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103357","article-title":"Effect of body mass index on treatment response of biologic\/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review","volume":"22","author":"Gialouri","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.001_bib29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.autrev.2016.01.010","article-title":"Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy","volume":"15","author":"Iannone","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rdc.2025.07.001_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X241271886","article-title":"Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy","volume":"16","author":"Williams","year":"2024","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.001_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-019-1810-5","article-title":"Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study","volume":"21","author":"Klingberg","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.001_bib32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13075-020-02350-5","article-title":"Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up","volume":"22","author":"Klingberg","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.001_bib33","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/BOR.0000000000000949","article-title":"The impact of dietary interventions in psoriatic arthritis","volume":"35","author":"Maharaj","year":"2023","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.001_bib34","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3390\/nu15051297","article-title":"Uncovering barriers and facilitators of weight loss and weight loss maintenance: insights from qualitative research","volume":"15","author":"Tay","year":"2023","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.001_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.34","article-title":"Obesity","volume":"3","author":"Gonz\u00e1lez-Muniesa","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2025.07.001_bib36","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/rheumatology\/keaa039","article-title":"Enthesitis in psoriatic arthritis (Part 1): pathophysiology","volume":"59","author":"Araujo","year":"2020","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.001_bib37","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1007\/s10067-021-05739-y","article-title":"Psoriatic arthritis and physical activity: a systematic review","volume":"40","author":"Kessler","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.001_bib38","first-page":"189","article-title":"Psoriasis and exercise: a review","volume":"12","author":"Yeroushalmi","year":"2022","journal-title":"Psoriasis (Auckl)"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.001_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237598","article-title":"Psoriatic disease and body composition: a systematic review and narrative synthesis","volume":"15","author":"Blake","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.001_bib40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13075-023-03085-9","article-title":"More than skin-deep: visceral fat is strongly associated with disease activity, function and metabolic indices in psoriatic disease","volume":"25","author":"Blake","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2025.07.001_bib41","first-page":"S32","article-title":"The role of the multidisciplinary team in the management of psoriatic arthritis","volume":"20","author":"Jadon","year":"2022","journal-title":"Muscoskel Care"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.001_bib42","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/nu11030601","article-title":"The impact of intermittent fasting (ramadan fasting) on psoriatic arthritis disease activity, enthesitis, and dactylitis: a multicentre study","volume":"11","author":"Adawi","year":"2019","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.001_bib43","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.001_bib44","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.rdc.2025.07.001_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/10742484221146371","volume":"27","author":"Muzurovi\u0107","year":"2022","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.rdc.2025.07.001_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101213","article-title":"Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis","volume":"42","author":"Vosoughi","year":"2021","journal-title":"eClinicalMedicine"},{"issue":"24","key":"10.1016\/j.rdc.2025.07.001_bib47","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2025.07.001_bib48","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fendo.2020.00190","article-title":"Prospect of sodium-glucose co-transporter 2 inhibitors combined with insulin for the treatment of type 2 diabetes","volume":"11","author":"Yang","year":"2020","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.001_bib49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.rdc.2025.07.001_bib50","article-title":"Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient","volume":"2021","author":"Costanzo","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"17","key":"10.1016\/j.rdc.2025.07.001_bib51","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2025.07.001_bib52","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.001_bib53","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial","volume":"6","author":"Saxena","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rdc.2025.07.001_bib54","unstructured":"Therapeutics A. Aardvark therapeutics, inc., announces the initiation of enrollment for three phase 2 clinical trials of oral ARD-101. 2025. Available at: https:\/\/aardvarktherapeutics.com\/aardvark-therapeutics-inc-announces-the-initiation-of-enrollment-for-three-phase-2-clinical-trials-of-oral-ard-101\/."},{"issue":"8","key":"10.1016\/j.rdc.2025.07.001_bib55","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cpdd.1100","article-title":"First-in-human evaluation of oral denatonium acetate (ARD-101), a potential bitter taste receptor agonist: a randomized, double-blind, placebo-controlled phase 1 trial in healthy adults","volume":"11","author":"Niethammer","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.rdc.2025.07.001_bib56","unstructured":"Nordisk N. Novo Nordisk successfully completes phase 1b\/2a trial with subcutaneous amycretin in people with overweight or obesity. 2025. Available at: https:\/\/www.biospace.com\/press-releases\/novo-nordisk-successfully-completes-phase-1b-2a-trial-with-subcutaneous-amycretin-in-people-with-overweight-or-obesity."},{"issue":"5","key":"10.1016\/j.rdc.2025.07.001_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2025.109021","article-title":"SGLT-2 inhibitors on cardiac autonomic function in individuals with and without type 2 diabetes mellitus","volume":"39","author":"\u00d6zel","year":"2025","journal-title":"J Diabetes Complications"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.001_bib58","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.001_bib59","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/ced.15385","article-title":"Association between sodium-glucose co-transporter 2 inhibitors and risk of psoriasis in patients with diabetes mellitus: a nationwide population-based cohort study","volume":"47","author":"Ma","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.001_bib60","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jid.2020.05.115","article-title":"Characterization of PCSK9 in the blood and skin of psoriasis","volume":"141","author":"Garshick","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2025.07.001_bib61","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.ihj.2023.12.011","article-title":"Role of PCSK9 inhibitors in the management of dyslipidaemia","volume":"76","author":"Nair","year":"2024","journal-title":"Indian Heart J"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.001_bib62","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/0976-500X.195906","article-title":"Proprotein convertase subtilisin\/kexin type 9 enzyme inhibitors: an emerging new therapeutic option for the treatment of dyslipidemia","volume":"7","author":"Mazhar","year":"2016","journal-title":"J Pharmacol Pharmacother"},{"issue":"16","key":"10.1016\/j.rdc.2025.07.001_bib63","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.rdc.2025.07.001_bib64","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.001_bib65","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41572-024-00563-5","article-title":"Metabolic syndrome","volume":"10","author":"Neeland","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.001_bib66","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/1756-185X.14147","article-title":"Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis","volume":"24","author":"Loganathan","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.rdc.2025.07.001_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109924","article-title":"Geographic distribution of metabolic syndrome and its components in the general adult population: a meta-analysis of global data from 28 million individuals","volume":"188","author":"Noubiap","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.001_bib68","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1097\/RHU.0000000000001738","article-title":"Prevalence of metabolic syndrome in psoriatic arthritis: systematic literature review and results from the CARMA cohort","volume":"28","author":"Urruticoechea-Arana","year":"2022","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.001_bib69","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/1756-185X.12134","article-title":"Metabolic syndrome in psoriatic arthritis patients: a cross-sectional study","volume":"16","author":"Sharma","year":"2013","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.001_bib70","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1136\/annrheumdis-2011-201273","article-title":"Obesity and risk of incident psoriatic arthritis in US women","volume":"71","author":"Li","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.001_bib71","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10067-017-3975-0","article-title":"Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study","volume":"37","author":"Caso","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.001_bib72","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5152\/eurjrheum.2017.16052","article-title":"Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis","volume":"4","author":"\u00d6zkan","year":"2017","journal-title":"Eur J Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.001_bib73","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.140021","article-title":"High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease","volume":"41","author":"Haroon","year":"2014","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.001_bib74","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/met.2009.0124","article-title":"Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis","volume":"8","author":"Raychaudhuri","year":"2010","journal-title":"Metab Syndr Relat Disord"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.001_bib75","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","article-title":"Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers","volume":"73","author":"Di Minno","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.001_bib76","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/bjd.17741","article-title":"Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A Critically Appraised Topic","volume":"181","author":"Mahil","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T23:28:50Z","timestamp":1758583730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X25000468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0889857X25000468"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.001","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity and Comorbidity Management in Psoriatic Arthritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}